We previously found GAS5 was detectable and stable in the plasma of NSCLC patients and GAS5 expression levels could be used to distinguish NSCLC patients from control patients with an area under the ROC of 0.832 40. The gene discussed is GAS5; the disease is non-small cell lung carcinoma.